摘要
目的探讨导致阿帕替尼治疗恶性肿瘤致血压升高的危险因素。方法选取赣南医学院第一附属医院2018年1月~2019年12月收治的240例恶性肿瘤患者为研究对象,按照治疗方式的不同分为观察组与对照组,各120例。观察组采用阿帕替尼治疗,对照组行常规治疗,未服用阿帕替尼治疗。比较对两组的血压升高发生率。同时对观察组患者的一般资料进行回顾性分析,并通过单因素分析及Logistic回归分析方式评估引发高血压的常见危险因素。结果观察组患者的高血压发生率为35.0%,高于对照组的10.0%(P<0.05)。两组中继发高血压患者均未出现高血压危象,且经药物治疗后血压情况均得到控制。单因素分析显示,患者年龄、吸烟史、体重指数(BMI)、美国东部肿瘤协作组(ECOG)评分、用药剂量等因素和阿帕替尼所致继发性高血压发生有关(P<0.05);Logistic回归分析显示,年龄是导致阿帕替尼所致继发性高血压的独立危险因素(P<0.05)。结论年龄与阿帕替尼所致继发性高血压发生有较大关联,临床上须加强对老年患者病情观察的重视。
Objective To explore the risk factors leading to increased blood pressure of Apatinib in the treatment of malignant tumors.Methods A total of 240 cases of malignant tumor patients in the First Affiliated Hospital of Gannan Medical College from January 2018 to December 2019 were selected as the research objects,and they were divided into the observation group and the control group according to different treatment methods,120 cases in each group.The observation group was treated with Apatinib,while the control group was treated with routine therapy,without Apatinib.The incidence of increased blood pressure were compared between the two groups.At the same time,the general data of patients in the observation group were retrospectively analyzed,and the common risk factors of hypertension were evaluated by univariate analysis and Logistic regression analysis.Results The incidence of hypertension in the observation group was 35.0%,which was higher than that in the control group(10.0%)(P<0.05).There was no hypertension crisis in the two groups,and the blood pressure was controlled after drug treatment.Univariate analysis showed that age,smoking history,body mass index(BMI),Estern Cooperative Oncology Group(ECOG)score,medication dose were related to the occurrence of secondary hypertension caused by apatinib(P<0.05).Logistic regression analysis showed that age was an independent risk factor for secondary hypertension caused by Apatinib(P<0.05).Conclusion Age is closely related to the secondary hypertension caused by Apatinib.It is necessary to pay more attention to the observation of elderly patients'condition.
作者
何苗
曹佐锋
黄莉
HE Miao;CAO Zuo-feng;HUANG Li(Department of Oncology,the First Affiliated Hospital of Gannan Medical College,Jiangxi Province,Ganzhou 341000,China)
出处
《中国当代医药》
2020年第35期136-139,共4页
China Modern Medicine
基金
江西省赣州市指导性科技计划项目(GZ2018ZSF069)。
